VEGF Antibody (C-1): sc-7269

VEGF Antibody (C-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects VEGF protein of mouse, rat, and human origin by WB, IP, IF, and IHCP. VEGF Antibody (C-1) is available in both non-conjugated and various conjugated forms, including agarose, HRP, PE, FITC, and multiple Alexa Fluor® conjugates. VEGF plays a crucial role in angiogenesis, the process of new blood vessel formation, which is vital for supplying nutrients and oxygen to tissues, particularly during development and in response to injury. VEGF is implicated in tumor progression, as VEGF promotes the growth of blood vessels that supply tumors, facilitating their growth and metastasis. VEGF exists as a dimeric glycoprotein and exhibits structural homology to platelet-derived growth factor (PDGF), with several isoforms generated through alternative mRNA splicing. In various staining applications, VEGF monoclonal antibody (C-1) demonstrates cytoplasmic localization, highlighting VEGF presence in tumor cells where VEGF is often overexpressed. Additionally, VEGF mRNA expression in primary tumors and VEGF production by tumor cell lines in vitro underscore VEGF significance in cancer biology. Notably, Flt, a member of the PDGF receptor family, has been identified as a high-affinity receptor for VEGF, further emphasizing VEGF importance in both normal physiological processes and pathological conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VEGF Antibody (C-1) References:

1. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.  |  Plate, KH., et al. 1992. Nature. 359: 845-8. PMID: 1279432
2. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.  |  de Vries, C., et al. 1992. Science. 255: 989-91. PMID: 1312256
3. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.  |  Berse, B., et al. 1992. Mol Biol Cell. 3: 211-20. PMID: 1550962
4. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.  |  Breier, G., et al. 1992. Development. 114: 521-32. PMID: 1592003
5. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.  |  Tischer, E., et al. 1991. J Biol Chem. 266: 11947-54. PMID: 1711045
6. The vascular endothelial growth factor family of polypeptides.  |  Ferrara, N., et al. 1991. J Cell Biochem. 47: 211-8. PMID: 1791185
7. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line.  |  Conn, G., et al. 1990. Proc Natl Acad Sci U S A. 87: 1323-7. PMID: 2406719
8. Induction of angiogenesis during the transition from hyperplasia to neoplasia.  |  Folkman, J., et al. 1989. Nature. 339: 58-61. PMID: 2469964
9. VEGF - A Stimulus for Neuronal Development and Regeneration in the CNS and PNS.  |  Theis, V. and Theiss, C. 2018. Curr Protein Pept Sci. 19: 589-597. PMID: 29299985
10. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.  |  Melincovici, CS., et al. 2018. Rom J Morphol Embryol. 59: 455-467. PMID: 30173249
11. Targeting VEGF-neuropilin interactions: a promising antitumor strategy.  |  Peng, K., et al. 2019. Drug Discov Today. 24: 656-664. PMID: 30315890
12. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium.  |  Zhang, L., et al. 1998. J Pathol. 185: 402-8. PMID: 9828839

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VEGF Antibody (C-1) has 1,270 citations in a variety of scientific publications.

Primary antibodies like Anti-VEGF Antibody (C-1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VEGF Antibody (C-1) Specifications

Alternate Product Name: VEGF

Product Clone Name: C-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-140/

Epitope Target: VEGF

Epitope Species: human

Product Reactivity/Detection: the 189, 165 and 121 amino acid splice variants of VEGF

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1,270 citations in various scientific publications

Available Conjugates/Forms for VEGF Antibody (C-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin